You are here
Sunday, May 18, 2008
Researchers Develop First Transgenic Monkey Model of Huntington’s Disease
Experts See Model as Tool to Better Understand the Disease, Develop More Effective Therapies, and Lead the Way to Similar Models for Other Genetic Diseases
Scientists have developed the first genetically altered monkey model that replicates some symptoms observed in patients with Huntington's disease, according to a new study funded by the National Institutes of Health. Researchers are now able to better understand this complex, devastating and incurable genetic disorder affecting the brain. This advance, reported in the May 18 advance of online publication edition of Nature, could lead to major breakthroughs in the effort to develop new treatments for a range of neurological diseases.
Huntington’s is an inherited disease caused by a defective gene that triggers certain nerve cells in the brain to die. Symptoms may include uncontrolled movements, mood swings, cognitive decline, balance problems, and eventually losing the ability to walk, talk or swallow. It affects five to 10 people in every 100,000. There is no known treatment to halt progression of the disease, only medications to relieve symptoms. Death typically occurs 15 to 20 years after onset.
This study marks the first time that researchers have developed a rhesus macaque model of a specific human disease using transgenic technologies, a marked improvement over mouse models. Transgenic animals are created using a recombinant DNA method to modify a genome.
"This research allows scientists to advance beyond mouse models which do not replicate all of the changes in the brain and behavior that humans with Huntington’s disease experience," said John D. Harding, Ph.D., director of primate resources at the NIH’s National Center for Research Resources (NCRR), which funded the study. "Primate models better mirror human diseases and are a critical link between research with small laboratory animals and studies involving humans."
To unravel the genetic components of this disease, NIH-supported researchers Anthony W.S. Chan, D.V.M., Ph.D.; Xiao-Jiang Li, M.D., Ph.D.; and Shi-Hua Li, M.D., Ph.D., collaborated with their colleagues at the Yerkes National Primate Research Center and other components of Emory University in Atlanta. The research was supported by the NCRR and the National Institute of Neurological Disorders and Stroke (NINDS) at NIH.
The Emory research team developed this transgenic monkey model by introducing altered forms of the Huntington gene into monkey eggs using a viral vector. The eggs were fertilized and the resulting embryos were introduced into surrogate mothers, resulting in five live births. The investigators are now studying the onset of the disease and its behavioral and cognitive effects, with the goal of using the monkey model to better understand disease mechanisms and to design therapies.
"Genetic advances make it easy to identify who has inherited the disease gene," said Walter Koroshetz, M.D., deputy director of the NINDS. "Now, with a primate model of Huntington’s disease, we are one large step closer to finding better treatments for people with the disease as well as those destined to develop it."
The Yerkes primate center where this advance was made is one of eight supported by NCRR. The centers provide leadership, training and resources to foster scientific discovery and compassionate, quality animal care. Last year, the eight centers located around the country supported more than 2,000 researchers studying a wide range of diseases using non human primate models.
"Yerkes primate center is an ideal place to carry out this work because of its expertise in nonhuman primate transgenesis, non-invasive neural imaging, and experience with behavior assessment," said Dr. Harding.
For more information about Huntington’s disease, visit: www.ninds.nih.gov/disorders/huntington/huntington.htm.
NCRR, a part of NIH, provides laboratory scientists and clinical researchers with the resources and training they need to understand, detect, treat and prevent a wide range of diseases. NCRR supports all aspects of translational and clinical research, connecting researchers, patients, and communities across the nation. For more information, visit www.ncrr.nih.gov.
The NINDS (www.ninds.nih.gov) is the nation’s primary supporter of biomedical research on the brain and nervous system.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®